Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 46.31% is 76% above its 5-year average of 26.38%, near the high end of its 5-year range (-14.58%–50.66%).
0.22% below its 12-month average of 46.41%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 48.55%.
GROSS MARGIN
46.31%
GROSS MARGIN AVG TTM
46.41%
GROSS MARGIN AVG 3Y
32.32%
GROSS MARGIN AVG 5Y
26.38%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-0.22%
CURRENT VS 3Y AVG
+43.29%
CURRENT VS 5Y AVG
+75.56%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+11.91%
vs the sector median at left
Market Cap
$120.92M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$120.43M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$122.13M
Gross Margin
-62.76%
TTM Avg
-61.84%
3Y Avg
-230.63%
5Y Avg
-163.28%
Market Cap
$119.44M
Gross Margin
0.00%
TTM Avg
50.00%
3Y Avg
50.00%
5Y Avg
33.33%
Market Cap
$118.84M
Gross Margin
90.14%
TTM Avg
48.16%
3Y Avg
49.08%
5Y Avg
32.72%
Market Cap
$116.35M
Gross Margin
99.91%
TTM Avg
-67.10%
3Y Avg
-31.47%
5Y Avg
-20.98%
Market Cap
$125.14M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Seer, Inc. (SEER) | $121.19M | 46.31% | 46.41% | 32.32% | 26.38% |
| enGene Holdings Inc. (ENGN)vs › | $120.92M | 0.00% | 0.00% | 0.00% | 0.00% |
| Tenaya Therapeutics, Inc. (TNYA)vs › | $120.43M | 0.00% | 0.00% | 0.00% | 0.00% |
| Cibus, Inc. (CBUS)vs › | $122.13M | -62.76% | -61.84% | -230.63% | -163.28% |
| Spruce Biosciences, Inc. (SPRB)vs › | $119.44M | 0.00% | 50.00% | 50.00% | 33.33% |
| BGM Group Ltd. (BGM)vs › | $119.26M | 12.79% | 14.59% | 10.64% | 11.25% |
| LENZ Therapeutics, Inc. (LENZ)vs › | $118.84M | 90.14% | 48.16% | 49.08% | 32.72% |
| Coya Therapeutics, Inc. (COYA)vs › | $116.35M | 99.91% | -67.10% | -31.47% | -20.98% |
| TuHURA Biosciences, Inc. (HURA)vs › | $125.14M | 0.00% | 0.00% | 0.00% | 0.00% |
| Tonix Pharmaceuticals Holding Corp. (TNXP)vs › | $125.06M | 34.65% | 28.86% | 24.17% | 16.11% |
Gross Margin
46.3%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 48.55% |
| 2026-03-31 | 33.07% |
| 2025-12-31 | 50.45% |
| 2025-09-30 | 49.33% |
| 2025-06-30 | 50.66% |
| 2025-03-31 | 48.28% |
| 2024-12-31 | 9.27% |
| 2024-09-30 | 46.88% |
| 2024-06-30 | 7.45% |
| 2024-03-31 | -4.34% |
| 2023-12-31 | 41.70% |
| 2023-09-30 | 15.81% |
| 2023-06-30 | 23.03% |
| 2023-03-31 | 18.80% |
| 2022-12-31 | 40.17% |
| 2022-09-30 | 22.30% |
| 2022-06-30 | 19.55% |
| 2022-03-31 | 11.14% |
| 2021-12-31 | -14.58% |
| 2021-09-30 | 22.33% |
| 2021-06-30 | 14.09% |
| 2021-03-31 | 100.00% |
| 2020-12-31 | -41.07% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 100.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | -258.62% |
